Thumbnail
Access Restriction
Open

Author Campbell, Jamie ♦ Lowe, David ♦ Sleeman, Matthew A.
Source PubMed Central
Content type Text
Publisher Blackwell Science Inc
File Format PDF
Date Created 2010-12-23
Language English
Difficulty Level Medium
Subject Domain (in DDC) Technology ♦ Medicine & health
Subject Keyword Pharmacology
Abstract Rheumatoid arthritis is one of the commonest autoimmune diseases affecting 0.8% of the population. Over the last decade the treatment of this chronic disease has been revolutionized by the use of monoclonal antibodies and fusion proteins, targeting molecules like tumour necrosis factor alpha. Nevertheless, approximately one-third of subjects fail to respond to these therapies and therefore significant unmet medical need remains. Following a decade of use, clinical, government and regulatory agency expectations have changed for new antibodies therapies entering this highly competitive area. In this review, we discuss the current advances being made in antibody engineering and how they are being considered and used in the development of the next generation of antibodies to meet future expectations of healthcare providers, physicians and patients. Moreover, we discuss how pattern recognition receptors may provide new antibody tractable targets that may break the cycle of autoimmunity in rheumatoid arthritis.
ISSN 00071188
Age Range above 22 year
Educational Use Research
Interactivity Type Expositive
Education Level UG and PG
Learning Resource Type Article
Publisher Date 2011-04-01
Rights Holder Blackwell Science Inc
e-ISSN 14765381
Journal British Journal of Pharmacology
Volume Number 162
Issue Number 7
Page Count 15
Starting Page 1470
Ending Page 1484


Open content in new tab

   Open content in new tab
Source: PubMed Central